The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept

Mariusz Mogielnicki; Damian Swieczkowski; Witold Bachorski; Grzegorz Zuk; Natasza Gilis-Malinowska; Aleksander Zarzeka; Piotr Merks; Marcin Gruchala; Milosz Jaguszewski

doi:10.5603/CJ.2016.0074

Vol 23, No 5 (2016)

CLINICAL CARDIOLOGY - LETTER TO THE EDITOR

Submitted: 2016-09-10

Accepted: 2016-09-10

Published online: 2016-10-06

View PDF

Download PDF file

Get Citation

The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept

Mariusz Mogielnicki, Damian Swieczkowski, Witold Bachorski, Grzegorz Zuk, Natasza Gilis-Malinowska, Aleksander Zarzeka, Piotr Merks, Marcin Gruchala, Milosz Jaguszewski

DOI: 10.5603/CJ.2016.0074

Pubmed: 27723064

Cardiol J 2016;23(5):515-517.

Vol 23, No 5 (2016)

CLINICAL CARDIOLOGY - LETTER TO THE EDITOR

Submitted: 2016-09-10

Accepted: 2016-09-10

Published online: 2016-10-06

Abstract

Not available

Abstract

Not available

Full Text:

View PDF

Download PDF file

Get Citation

About this article

Title

The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) perspective on cardiovascular Polypill: A multidimensional concept

Journal

Cardiology Journal

Issue

Vol 23, No 5 (2016)

Pages

515-517

Published online

2016-10-06

Page views

1428

Article views/downloads

1703

DOI

10.5603/CJ.2016.0074

Pubmed

27723064

Bibliographic record

Cardiol J 2016;23(5):515-517.

Authors

Mariusz Mogielnicki
Damian Swieczkowski
Witold Bachorski
Grzegorz Zuk
Natasza Gilis-Malinowska
Aleksander Zarzeka
Piotr Merks
Marcin Gruchala
Milosz Jaguszewski